6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of February 2024

Commission File Number: 001-41084

NeuroSense Therapeutics Ltd.
(Translation of registrant’s name into English)

11 HaMenofim Street, Building B

Herzliya 4672562 Israel
+972-9-7996183
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

NeuroSense Therapeutics Ltd. (the “Company”) has made available an updated presentation about its business (the “Presentation”), a copy of which is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The Presentation includes additional positive clinical outcomes of Quality of Life and complication-free survival data on slides 27-31 and drug tolerability data on slide 18.

The new update in the Presentation is not an admission as to the materiality of any information therein. The information contained in the Presentation is summary information that should be considered in the context of the Company’s filings with the Securities and Exchange Commission and other public announcements the Company may make by press release or otherwise from time to time.

Exhibit Index

Exhibit No.	Description
99.1	Presentation, dated February 2024

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NeuroSense Therapeutics Ltd.
Date: February 22, 2024	By:	/s/ Alon Ben-Noon
		Alon Ben-Noon
		Chief Executive Officer

2

EX-99.1

Exhibit 99.1

February 2024 Nasdaq: NRSN

Forward - Looking Statements This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties . All statements contained in this presentation other than statements of historical facts, including our business strategy and plans and objectives for future operations, including our financial performance, are forward looking statements . The words " anticipate"," believe," "continue," "estimate," "expect," "intend," "may," "will" and similar expressions are intended to identify forward looking statements . We have based these forward - looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short term and long - term business operations and objectives and financial needs . Forward looking statements made in this presentation include statements about the timing of reporting neurofilament and biomarker results from our ALS Phase 2 b clinical trial and of other clinical and regulatory milestones, including target market and opportunities for our product candidates ; our expectations regarding our competitive advantages ; the planned development timeline of our product candidates ; and characterizations of the pre - clinical and clinical trial results of our product candidates . Forward looking statements are subject to a number of risks and uncertainties and represent our views only as of the date of the presentation . The future events and trends discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward - looking statements due to, among other things, a delay in the reporting of neurofilament and biomarker results from our ALS Phase 2 b clinical trial , a delay in other clinical and regulatory milestones, and the development and commercial potential of any product candidates . More information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Annual Report on Form 20 - F filed with the Securities and Exchange Commission on March 22 , 2023 and the Company's subsequent filings with the SEC . We undertake no obligation or duty to update information contained in these forward - looking statements, whether as a result of new information, future events or otherwise . Trademarks in this presentation are the property of their respective owners and used for informational and educational purposes only . 2

NeuroSense Highlights Developing novel therapies for neurodegenerative diseases of high unmet need Significant top line results from Phase 2b study for ALS 1 Additional catalysts expected: Neurofilament results (Q1 2024) Biomarker results (H1 2024) Existing partnership with big pharma, and fully funded through Q2 2024 1 ALS - Amyotrophic Lateral Sclerosis, also referred to as Lou Gehrig ’ s Disease 3

Focused Pipeline Diseases with Limited Treatment Options and High Commercial Opportunity ALS • NfL 1 (Q 1 2024 ) • Biomarker data (H 1 2024 ) Discovery Pre - clinical Phase 1 Phase 2 Phase 3 NDA Indication Next Milestone Parkinson ’ s • Exploring potential co - development Alzheimer ’ s • Completion of Phase 2 enrollment (H 2 2024 ) 1 NfL: Neurofilament 4

~ 24 % Growth in Patients by 2040 in the US and EU 2 > 80,000 ALS Patients in NeuroSense ’ s planned target market 2 + 5,000 New cases of ALS each y ear (US) 1 3 Annual Market Opportunity ~$ 3 B 1 Johns Hopkins Medicine 2 Projected increase in amyotrophic lateral sclerosis from 2015 to 2040 , Nature Communications, 2016 3 Management estimate ALS is an incurable neurodegenerative disease, causing complete paralysis and ultimately death within 2 - 5 years from diagnosis 5

A Unique Synergistic Formulation With A Powerful Outcome Celecoxib - an NSAID which reduces: • Neuroinflammation • Glutamate excitotoxicity • Oxidative stress Ciprofloxacin - a fluoroquinolone which regulates: • MicroRNA synthesis • Iron accumulation PrimeC is a novel formulation , consisting of specific doses of two FDA - approved drugs, designed to work synergistically on more than one target in ALS PrimeC ’ s effect on pathways which lead to neuron death in ALS 6

Synergistic Benefit: In - Vitro & In - Vivo This finding is attributed to Celecoxib blocking exit of Ciprofloxacin in the neuron PrimeC ’ s combination ( Celecoxib + Ciprofloxacin ) remained at a higher concentration in rodent brain tissue for longer , when compared to administration of Ciprofloxacin alone *** 7 Synergistic Mode of Action Improved Pharmacokinetic (PK) Profile

* = p< 0.05 , *** = p< 0.001 PrimeC Demonstrated Statistically Significant Efficacy in Key Pre - Clinical Study * p< 0.05 ***p< 0.001 Studies were conducted in the laboratory of Dr. Justin Ichida, University of Southern California, using an induced Pluripotent Stem Cell ( iPSC) Model Generated from People Living with ALS * *** *** *** * NeuroSense H e a l t h y C o n t r o l ( 5 2 8 0 n = 1 0 0 ) N e u r o S e n s e + 3 µ M ( n = 2 0 0 ) A m y l y x + 3 µ M ( n = 2 0 0 ) D e x p r a m i p e x o l e + 3 µ M ( n = 1 6 8 ) D i h y d r o t e s t o s t e r o n e + 3 µ M ( n = 2 0 0 ) R a d i c a v a + 3 µ M ( n = 1 7 0 ) T o l m e t i n + 3 µ M ( n = 1 6 8 ) P 0 2 1 + 1 µ M ( n = 1 7 0 ) h A t a x i n 2 A S O + 9 µ M ( n = 1 5 0 ) I b u d i l a s t + 3 µ M ( n = 1 2 0 ) C u r c u m i n + 3 µ M ( n = 1 5 0 ) 0.0 0.5 1.0 1.5 2.0 H a z a r d R a t i o Candidate Compounds on sALS30 iMN Survival Amylyx Mitsubishi Tanabe Candidate compounds on sALS 30 iMN survival Hazard ratio NeuroSense 1 Radicava is a registered trademark of Mitsubishi Tanabe Pharma Corporation Independent, non - sponsored research Collaboration with Dr. Ichida Isolated PBMCs iPSCs iPSC - derived motor neurons + / - treatments iPSC - derived cortical neurons Differentiation Reprogramming Therapeutic Test ALS patient blood

Healthy ALS ALS + PrimeC PrimeC Demonstrated Statistically Significant Efficacy in vivo 1 . Improved Motor Performance Healthy control mSod 1 ALS model mSod 1 ALS +PrimeC 2 . Recovered Neuronal Structure ALS ALS + PrimeC

A synchronized PK profile of the two compounds, potentially maximizes the synergy between them PrimeC Unique Formulation Induces a Synchronized PK Profile 10 0 2 4 6 8 10 12 0 500 1000 1500 2000 2500 Time (h) C o n c e n t r a t i o n ( n g / m l ) PrimeC ciprofloxacin Ref ciprofloxacin PrimeC celecoxib Ref celecoxib PK profile studies in humans Synchronized peak IR T max ER T max ER Tmax doubled IR Tmax

These results led NeuroSense to commence a Phase 2 b clinical study, using an improved new extended - release formulation of PrimeC Significant changes in ALS - related biomarkers Well tolerated, no drug related SAEs Reduced functional and respiratory deterioration NST 002 15 patients Open - Label Intermediate formulation of PrimeC 12 - month dosing Clinic visit every 3 months Phone visit every 1.5 months Location: Tel Aviv Sourasky Medical Center PrimeC Met Primary Endpoints & Exploratory Endpoints in Phase 2 a Study 11

Screening (N= 73 ) PrimeC (N= 45 ) Placebo (N= 23 ) Baseline 180 60 120 Clinical visits (Days) Double Blind - 6 Months (N= 68 ) PrimeC Open Label Extension 12 Months ~ 90 % of patients in PrimeC and Placebo groups were co - treated with Riluzole PARADIGM used P rimeC ’ s novel extended - release formulation PrimeC Phase 2 b Trial Design Randomized, Prospective, Double - Blind, Placebo - Controlled Study • 4 Screen Failures • One participant misdiagnosed for ALS Randomization

Primary Endpoints • Safety and Tolerability Measures • ALS - Hallmark Biomarker Measures of TDP - 43 and ProstaglandinJ 2 (results expected H 1 2024 ) Secondary Efficacy Endpoints • ALSFRS - R (ALS Functional Rating Scale) • SVC (Slow Vital Capacity) • PROMIS - 10 quality of life questionnaire • Complication Free Survival Exploratory Endpoint • King's/ MiToS • Neurofilaments (results expected Q 1 2024 ) PrimeC Phase 2 b Trial Endpoints

PrimeC Phase 2 b Study Inclusions / Exclusions Inclusion Criteria • Males or females between the ages of 18 and 75 years of age • Diagnosis of familial or sporadic ALS • Disease duration less than 30 months prior to screening • Pre - enrollment ALSFRS - R slope from disease onset ≥ 0 . 3 points per month • ALSFRS - R at screening ≥ 25 • Item 3 (swallowing) in ALSFRS - R ≥ 3 • Subjects may be treated in parallel with Riluzole and/or Edaravone and/or Sodium Phenylbutyrate/TUDCA • Upright slow vital capacity (SVC) ≥ 60 % • 18 < BMI < 30 Exclusion Criteria • Patients with known hypersensitivity to celecoxib or ciprofloxacin and related exclusions derivative from the celecoxib and ciprofloxacin labels 14

PrimeC Phase 2b Study ITT and PP Pre - specified Analyses PP (N= 62 ) ITT (N= 68 ) n=43 n=45 PrimeC n=19 n=23 Placebo Intent to Treat (ITT) and Per Protocol (PP) are both pre - specified analyses within the study ITT assesses the effect of the treatment on all patients enrolled in the study while PP analysis includes only patients who strictly adhered to the study protocol 1 Both analyses are valid, yet PP best answers the question of what is the effect of receiving the treatment on a group of patients versus the effect of assigning the treatment to a group of patients 1 1 Tripepi G, Chesnaye NC, Dekker FW, Zoccali C, Jager KJ. Intention to treat and per protocol analysis in clinical trials. Neph rol ogy. 2020 ; 25:513 – 517 . 15 Analysis Pre - defined populations

PrimeC Phase 2b Study: Well Balanced Enrollment Male Female Age Height (cm) Weight (kg) BMI (kg/m 2 ) TRICALS Risk Profile Patients on background ALS therapy PP Analysis (PrimeC= 43 ; Placebo= 19 ) ALSFRS - R at baseline % Predicted SVC at baseline Placebo n= 23 60.9 % 39.1 % 54.9 171.2 71.1 24.0 - 4.4 87 % 37.9 83.9 PrimeC n=45 60.0% 40.0% 59.1 170.8 70.6 24.1 - 4.2 91% 37.9 89.4 16

Placebo (N=2 3 ) PrimeC (N=45) Summary of All Adverse Events 65.2% 68.9% Adverse Events (AE) 65.2% 68.9% Treatment - Emergent AEs (TEAE) 4.3% 20.0% Study Drug Related Treatment - Emergent AEs (TEAE) 8.6% 8.9% Serious Treatment - Emergent AEs (TEAE) 4.3% 4.4% Subject death 4.3% 6.7% TEAE leading to Study Drug Discontinuation 0.0% 0.0% TEAE leading to Study Drug Reduction 8.6% 15.6% TEAE leading to Study Drug Interruption PrimeC Phase 2b Study Results Achieved Primary Endpoints with a Safety and Tolerability Profile Comparable to Placebo 17 All Adverse Events Were Transient and Expected No Drop - outs Due To Adverse Events

PrimeC Phase 2b Study Results Achieved Primary Endpoints with a D rug T olerability Profile Comparable to Placebo Tolerability is defined as time - to - discontinuation or completion of assigned study medication during the double - blind period since randomization PrimeC Placebo N=5 of 45 N= 4 of 24

Phase 2 b Study Results – ITT Analysis PrimeC Attenuated Disease Progression By 29.2 % Difference in ALSFRS - R *p - value= 0.12

20 (N= 43 ) (N=19) Phase 2 b Study Results – PP Analysis PrimeC Significantly Attenuated Disease Progression by 37 % in ALSFRS - R (p= 0.03 )

Losing or Keeping a Single Point On the ALSFRS - R May Have a Significant Impact A 1 - point decrease in the hands' Functional Loss Score can represent a transition from independent feeding to requiring assistance. A 1 - point drop on the swallowing assessment scale can mark the critical threshold between self - sufficiency and the necessity of supplemental tube feeding. A 1 - point stumble in the legs can be the difference between walking with a cane and not being able to walk at all. A 1 - point loss in breathing can cause a transition from independent breathing to requiring the use of a machine ventilator. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS - R: a revised ALS functional rating scale that incorporates assessments of r espiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999 ; 169 ( 1 - 2 ): 13 - 21 . doi: 10.1016 /s 0022 - 510 x( 99 ) 00210 - 5 21

Phase 2 b Study Results – ITT Analysis PrimeC Slowed Decline of Physical Functions vs Placebo Mean ALSFRS - R total score was 2.23 points higher at 6 months for PrimeC compared to placebo . 22 Placebo PrimeC - 7.64 - 5.41 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 Number of Points Lost ALSFRS - R Total Score 2.23 Point Difference (P= 0.12 )

Phase 2 b Study Results – ITT Analysis PrimeC Slowed Decline of Physical Functions vs Placebo 23 Background Respiratory failure is the most common cause of death from ALS - 1.25 - 0.84 -4 -3 -2 -1 0 Number of Points Lost Bulbar 0 . 41 Point Difference (P= 0.24 ) - 1.55 - 0.74 -4 -3 -2 -1 0 Number of Points Lost Respiratory 0.81 Point Difference (P= 0.13 ) - 2.41 - 2.01 -4 -3 -2 -1 0 Number of Points Lost Fine Motor 0.40 Point Difference (P= 0.51 ) - 2.61 - 2.11 -4 -3 -2 -1 0 Number of Points Lost Gross Motor 0.50 Point Difference (P= 0.34 ) Placebo PrimeC Bulbar: Speech Salivation Swallowing Respiratory: Dyspnea Orthopnea Respiratory insufficiency Fine Motor: Handwriting Cutting Food Dressing and hygiene Gross Motor: Turning in bed Walking Climbing stairs

Phase 2 b Study Results – PP Analysis PrimeC Slowed Decline of Physical Functions vs Placebo - 8.61 - 5.39 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 Number of Points Lost ALSFRS - R Total Score 3.22 Point Difference (P=0.03) Mean ALSFRS - R total score was 3.22 points higher at 6 months for PrimeC compared to placebo . Placebo PrimeC 24

Phase 2 b Study Results – PP Analysis PrimeC Slowed Decline of Physical Functions vs Placebo - 2.51 - 1.99 -4 -3 -2 -1 0 Number of Points Lost Fine Motor 0.52 Point Difference (P= 0.42 ) - 1.36 - 0.83 -4 -3 -2 -1 0 Number of Points Lost Bulbar 0.53 Point Difference (P= 0.16 ) - 2.94 - 2.10 -4 -3 -2 -1 0 Number of Points Lost Gross Motor 0.84 Point Difference (P= 0.14 ) - 1.71 - 0.57 -4 -3 -2 -1 0 Number of Points Lost Respiratory 1.14 Point Difference (P=0.04) 25 Background Respiratory failure is the most common cause of death from ALS Bulbar: Speech Salivation Swallowing Respiratory: Dyspnea Orthopnea Respiratory insufficiency Fine Motor: Handwriting Cutting Food Dressing and hygiene Gross Motor: Turning in bed Walking Climbing stairs Placebo PrimeC

Phase 2 b Study Results – ITT and PP Analysis Effect of treatment on Slow Vital Capacity (SVC) 26 (N= 43 ) (N= 19 ) p value = 0.5 ITT PP

Complication - Free Survival Probability Measures ALS Complications analysis includes death from any cause or respiratory insufficiency or hospitalization due to ALS - related complications The MiToS system uses six stages, from 0 to 5 and is based on functional ability (ALSFRS - R) stage 0 = normal function stage 5 = death The King ’ s system uses five stages from 1 to 5 based on disease burden (clinical involvement, feeding or respiratory failure) stage 1 = symptom onset stage 5 = death

PrimeC Increases Probability of Complication - Free Survival in distinct methods (ITT) Hazard Ratio (mean, 95% CI) King ’ s Stage - Free Survival MiToS Stage - Free Survival ALS Complication - Free Survival PrimeC reduces risk of death or complications 1 A hazard ratio of 1 means that there is no difference in survival between the two treatment arms. Hazard Ratio less than 1 means that survival was better in the PrimeC arm 0.52 (P= 0.1 ) 0.65 (P=0.31) 0.7 (P= 0.69 )

King ’ s Stage - Free Survival MiToS Stage - Free Survival ALS Complication - Free Survival PrimeC reduces risk of death or complications 1 Hazard Ratio (mean, 95 % CI) A hazard ratio of 1 means that there is no difference in survival between the two treatment arms. Hazard Ratio less than 1 means that survival was better in the PrimeC arm 0.47 (P= 0.07 ) 0.5 (P= 0.12 ) 0.34 (P= 0.29 ) PrimeC Increases Probability of Complication - Free Survival in distinct methods (PP)

- 6.4 - 5.7 -7.0 -6.0 -5.0 -4.0 -3.0 -2.0 -1.0 0.0 Placebo (N=23) PrimeC (N=45) No. of Points Lost PrimeC Slowed Decline in Quality of Life (ITT) 11.2 % (P= 0.68 ) - 5.5 - 4.6 -6.0 -5.0 -4.0 -3.0 -2.0 -1.0 0.0 Placebo (N=23) PrimeC (N=45) No. of Points Lost PROMIS - 10 Mental Health score PROMIS - 10 Physical Health score 15.5 % (P= 0.66 ) PROMIS (Patient - Reported Outcomes Measurement Information System) - 10 is a set of person - centered measures that evaluates and monitors physical, mental, and social health in individuals living with chronic conditions

- 5.8 - 4.8 -6.0 -5.0 -4.0 -3.0 -2.0 -1.0 0.0 Placebo (N=19) PrimeC (N=43) No. of Points Lost - 7.1 - 6.2 -8.0 -7.0 -6.0 -5.0 -4.0 -3.0 -2.0 -1.0 0.0 Placebo (N=19) PrimeC (N=43) No. of Points Lost PROMIS (Patient - Reported Outcomes Measurement Information System) - 10 is a set of person - centered measures that evaluates and monitors physical, mental, and social health in individuals living with chronic conditions 12.3 % (P= 0.65 ) 16.4 % (P= 0.64 ) PROMIS - 10 Mental Health score PROMIS - 10 Physical Health score PrimeC Slowed Decline in Quality of Life (PP)

NeuroSense is collaborating with leading KOLs and industry on the PARADIGM trial to elucidate PrimeC ’ s MOA via novel methodologies Biomarker Driven Proteomics Interplay Between TDP - 43 and RNA Regulation microRNA Profiling Identification of Novel Biomarkers Neurofilaments Neuronal Derived Exosomes Pioneering Approach to ALS Biomarker Research To Maximize Clinical Efforts 32

Alzheimer ’ s Donepezil + Memantine Parkinson ’ s Entacapone + levodopa/carbidopa ALS Sodium Phenybuterate + Taurursodiol SMA Onasemnogene + Nusinersen Epilepsy Lamotrigine + Valproate/Carbamazepine Successful combination strategies in neurology: Case Study: Amylyx (NASDAQ: AMLX) Market Cap: ~ $1 B (Jan 2024) Drug: ALS Combination Therapy of generic + supplement Price: $158,000/ year Estimated 2026 Sales: $1.1B/ year 1 The FDA approved Amylyx’s drug, AMX0035 (Relyvrio 2 ), in September 2022 after Phase 2 clinical trial attenuated diseases progression (ALSFRS - R) by 25% when compared to placebo 3 1 SVB Securities analyst Marc Goodman 2 Relyvrio is a registered trademark of Amylyx 3 Study results are not for comparison Proven Success of Combined Therapy 33

Novel combination therapy candidate of approved products optimized for PK and synergistic effects to address ALS and potentially other disease targets Robust clinical efficacy and excellent safety profile observed from ALS Phase 2 a and 2 b clinical studies • 37 % reduction in ALSFRS - R (p= 0.03 ) in phase 2 b study Patent coverage for novel formulation, method & combination (until 2038 ) Expedited and de - risked regulatory pathway (orphan drug designation / 505 (b) 2 pathway) PrimeC: Strong Clinical and Commercial Potential 34

Alzheimer ’ s (AD) Studies Reveal Potential Effect of NeuroSense ’ s Combination Therapy Biomarkers tested in Neuronal Derived Exosomes comparing non - treated Healthy vs. AD patients, to elucidate the potential target engagement of CogniC. Biomarker data were analyzed using a Mann - Whitney U test comparing AD samples with controls . *P< 0 . 05 , **P< 0 . 01 , ***P< 0 . 001 * 35

20 patients with mild to moderate AD 1:1 PrimeC to Placebo CogniC - intermediate formulation (= PrimeC - ER) 12 - month dosing Clinic visit every 3 months Single - center Target Engagement Biomarkers Secondary Efficacy Clinical Outcomes Primary Endpoint Safety & Tolerability 3 1 PrimeC PrimeC 2 AD Phase 2 Study Design Randomized, Prospective, Double - Blind, Placebo - Controlled Study 36

Senior Vice President at the Barrow Neurological Institute Chair of the Department of Neurology Prof. Jeremy Shefner (Chair) Dr. Jinsy Andrews Associate Professor of Neurology, Division of Neuromuscular Medicine, Columbia University Director of Neuromuscular Clinical Trials Prof. Merit Cudkowicz Chief of Neurology at Mass General and Director, Sean M. Healey & AMG Center for ALS Professor of Neurology at Harvard Medical School Prof. Jeffrey Rosenfeld Professor of Neurology and Associate Chairman of Neurology at Loma Linda University School of Medicine Medical Director of Center for Restorative Neurology at Loma Linda University Prof. Orla Hardiman Head of Academic Unit of Neurology at Trinity College Dublin and Consultant Neurologist at Beaumont Co - Chair of the European Consortium to Cure ALS and Chair of the Scientific Committee of ENCALS Exceptional Scientific Advisory Board 37

Key Collaborations 38

• Neurofilament Results • Biomarker Results • ALS End of Phase 2 Meeting with the FDA and EMA • Initiate ALS Phase 3 clinical study as needed Initiated ALS Phase 2 b PARADIGM study Received FDA IND Clearance for PrimeC Completed PK study single - dose & multi - dose successfully Completed In - life 90 - day GLP toxicology study successfully 2022 2023 2024 Completed Alzheimer ’ s biomarker study with positive results Completed Parkinson ’ s biomarker study with positive results Type D Meeting with the FDA Release ALS Phase 2 b clinical study top - line results Initiated Alzheimer ’ s Phase 2 study Milestones Achieved and Upcoming Potential Catalysts 39

Nasdaq: NRSN Thank You For more information: info@neurosense - tx.com 40